A Study to Characterize LY3314814 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of LY3314814 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects

Trial Profile

A Study to Characterize LY3314814 Pharmacokinetics as a Function of Dosing Duration and to Determine the Effect of LY3314814 on the Pharmacokinetics of CYP3A Substrates in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Lanabecestat (Primary) ; Donepezil; Midazolam; Midazolam; Simvastatin
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
    • 23 Apr 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Jul 2015, as reported by ClinicalTrials.gov.
    • 23 Apr 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top